Clinical experience in developing treatment regimens with the novel antipsychotic risperidone

International Clinical Psychopharmacology

Volumn 12, Issue SUPPL. 4, 1997, Pages

  Kopala, Lili C ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Extrapyramidal side effects; First episode psychosis; Risperidone; Schizophrenia; Treatment strategies

Indexed keywords

BENZATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

COGNITION; CONFERENCE PAPER; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; GUIDELINES; HUMANS; MALE; PATIENT COMPLIANCE; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 0030842796     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705002-00004     Document Type: Conference Paper

References (29)

1. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernández J, Gómez-Beneyto M, Schooler MR (1994) Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 151: 1819-1821.
2. Altman S, Honer WG, MacEwan GW, et al, (1995) Clozapine, risperidone and typical antipsychotics in severely ill patients with schizophrenia. Schizophr Res 15:153.
3. Borison RL, Consensus Study Group on Risperidone Dosing (1996) Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. Clin Ther 18:592-607.
4. Caliguri MP, Lohr JB, Jeste DV (1993) Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 150:1343-1348.
5. Chatterjee A, Chakos M, Koreen A, et al. (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152:1724-1729.
6. Chouinard G, Jones B, Remington G, et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40.
7. Chouinard G (1995) Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicenter risperidone study. J Clin Psychopharmacol 15 (suppl 1):36S-44S.
8. Davis JM, Andriukutis S (1986) The natural course of schizophrenia and effective maintenance therapy. J Clin Psychopharmacol 6 (suppl 1):2-10.
9. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
10. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988, 45:71-76.
11. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99 (suppl):S28-S31.
12. Flynn SW, Honer WG, Smith G, MacEwan GW, Altman S, Kopala LC (1996) Frontal lobe anatomy and risperidone response in schizophrenia [abstract NR92]. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association, New York, 4-9 May 1996. Washington, DC: American Psychiatric Association.
13. Gupta S, Andreasen NC, Arndt S, et al. (1995) Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. Am J Psychiatry 152: 191-196.
14. Gutierrez-Esteinou R, Grebb J (1997) Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 12 (suppl 4):S3-S10.
15. Heykants J, Huang M-L, Mannens G, et al. (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55 (suppl):13-17.
16. Honer WG, Smith GN, Lapointe JS, et al. (1995) Regional cortical anatomy and clozapine response in refractory schizophrenia. Neuropsychopharmacology 13:85-87.
17. Jones BD, Lemmens P (1995) Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia [abstract NR466]. In: 148th Annual Meeting of the American Psychiatric Association, Miami, 21-24 May 1995. Washington DC: American Psychiatric Association.
18. Kane JM, Woerner M, Lieberman J (1988) Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 8 (suppl 4):52-56.
19. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57: 103-107.
20. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476.
21. Kopala LC, Fredrikson D, Good KP, Honer WG (1996) Symptoms in neuroleptic-naive first-episode schizophrenia: response to risperidone. Biol Psychiatry 39:296-298.
22. Kopala LC (1996) Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand 94 (suppl):12-17.
23. Lieberman JA, Lobel SN (1993) Predictors of treatment response and course of schizophrenia. Curr Opin Psychiatry 6:63-69.
24. Lindström E, von Knorring L (1994) Changes in single symptoms and separate factors of the schizophenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 27: 103-108.
25. Loebel AD, Lieberman JA, Alir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR (1992) Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 149:1183-1188.
26. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
27. McEvoy J (1995) Dosing issues: target symptoms and dose response. Psychiatr Ann 25:297-300.
28. Peuskens J, Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726.
29. van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67-72.